Programmatic impact of Quantiferon-TB Gold in-Tube implementation on latent tuberculosis diagnosis and treatment in a public health clinic

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Shah, Maunank ^a   DiPietro, Danielle ^c   Greenbaum, Adena ^a   Ketemepi, Sherry ^b   Martins Evora, Maria ^b   Marsiglia, Vincent ^b   Dorman, Susan E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BALTIMORE CITY HEALTH DEPARTMENT   (United States)

^c TULANE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BHUTAN; COHORT ANALYSIS; COMMUNITY PROGRAM; CONTROLLED STUDY; DIAGNOSTIC VALUE; ERITREA; ETHIOPIA; ETHNICITY; FEMALE; HEALTH CENTER; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; IRAQ; LABORATORY DIAGNOSIS; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MYANMAR; MYCOBACTERIUM TUBERCULOSIS; NEPAL; RETROSPECTIVE STUDY; SPUTUM SMEAR; THORAX RADIOGRAPHY; TUBERCULIN TEST; ISOLATION AND PURIFICATION; METHODOLOGY; OUTPATIENT DEPARTMENT; UNITED STATES;

DIAGNOSTIC AGENT; GAMMA INTERFERON;

ADULT; AMBULATORY CARE FACILITIES; BALTIMORE; FEMALE; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; TUBERCULIN TEST; UNITED STATES;

EID: 84860635451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036551     Document Type: Article

References (15)

1. Advisory Council for the Elimination of Tuberculosis (ACET), (1999) Tuberculosis elimination revisited: obstacles, opportunities, and a renewed commitment. MMWR Recomm Rep 48: 1-13.
2. ATS/CDC/IDSA, (2005) Controlling tuberculosis in the United States. Am J Respir Crit Care Med 172: 1169-1227.
3. ATS/CDC/IDSA, (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 49: 1-51.
4. Ozuah PO, Burton W, Lerro KA, Rosenstock J, Mulvihill M, (1999) Assessing the validity of tuberculin skin test readings by trained professionals and patients. Chest 116: 104-106.
5. Pai M, Kalantri S, Dheda K, (2006) New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis. Expert Rev Mol Diagn 6: 413-422.
6. Pai M, Zwerling A, Menzies D, (2008) Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149: 177-184.
7. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, et al. (2010) Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 59: 1-25.
8. Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, et al. (2006) Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 6: 47.
9. Kunimoto D, Der E, Beckon A, Thomas L, Egedahl M, et al. (2009) Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis 13: 726-730.
10. Grinsdale JA, Ho CS, Banouvong H, Kawamura LM, (2011) Programmatic impact of using QuantiFERON(R)-TB Gold in routine contact investigation activities. Int J Tuberc Lung Dis 15: 1614-1620.
11. DHMH-Maryland, (2011) Maryland TB Statistics, Department of Health and Mental Hygiene. 1 Available: http://ideha.dhmh.maryland.gov/CTBCP/statistics.aspx. Accessed 2012 Jan.
12. Horsburgh CR Jr, Rubin EJ, (2011) Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 364: 1441-1448.
13. ATS/CDC/IDSA, (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161: S221-247.
14. Cellestis, (2006) Quantiferon-TB Gold (In-Tube Method) Package Insert. 1 Available: http://www.cellestis.com/IRM/Company/ShowPage.aspx?CPID=1171. Accessed 2011 Jul.
15. Herrera V, Perry S, Parsonnet J, Banaei N, (2011) Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 52: 1031-1037.